Project update for the final 6 months of ECLIPSE

We’ve been so busy on the project that we’ve neglected updating the website – apologies. As of 17 November 2017:

Phase 1 has now been completed. We have gathered data from 16 sites, involving 1,326 patients and 2,008 infusions. This took considerably longer to organise and collect than we had expected, and the data had to be cleaned so it was consistent across our 16 sites, e.g. so error ratings were comparable. We have submitted two papers and have a further two in draft form. One of the highlights of this phase of the project was feeding back results to sites – we prepared a report on the data for each site and held debriefs and focus groups to discuss this at those sites. This served well to give further detail about errors and the infusion practices at each site, and some sites planned to act on the results by reviewing policy, training and purchasing equipment to help nurses in their work.

Phase 2 involves deeper observations at 5 sites involved in Phase 1. Four of these sites have been completed the fifth will commence soon. We plan to develop papers on the error inducing factors that we have observed at this stage, and the positive deviations in practices too.

Phase 3 involves reaching our to stakeholders of intravenous infusion administration. We have been disseminating our emerging findings at conferences that clinicians and hospital management have been attending throughout the project. The latter stages of phase 3 involve organising three workshops, one with manufacturers, one with NHS stakeholders and one with patients and the public. We will be organising these shortly.

The project’s steering committee and advisory groups have met several times and have provided us with great guidance and feedback throughout.

To summarise, there should be some more published findings to share soon, we have some key research activities that are still to be do, and we need to draw all of this together for the end of March 2018 – so there’s still a lot to do but we’re making great progress.